EUVIMEDEUVIMED entdecken
Crossref

Neoadjuvant Lazertinib With or Without Chemotherapy in Patients With Resectable EGFR -Mutant Non–Small Cell Lung Cancer (NeoLazer): A Randomized, Multicenter, Phase II Trial

Dong Ki Lee, Se-Hoon Lee, Se Hyun Kim, Min Hee Hong, Chang Gon Kim, Ja Hyun Yeo, Byung Jo Park, Ha Eun Kim, Young Ho Yang, Tae Hee Hong, Inkyung Jung, Myung-Ju Ahn und 11 weitere

JCO Oncology Advances · 2026-10 · 3 (4)

DOI: 10.1200/oa-26-00082 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Oncology Advances, 2026-10. Verfasst von Dong Ki Lee und 22 weiteren Autor:innen. Die Arbeit nennt 10 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Lee, D. K., Lee, S., Kim, S. H., Hong, M. H., Kim, C. G., Yeo, J. H., Park, B. J., Kim, H. E., Yang, Y. H., Hong, T. H., Jung, I., Ahn, M., Ahn, J. S., Park, S., Park, S. Y., Cho, J. H., Lee, J., Jeon, Y. J., Kim, Y. J., …, & Kim, H. R. (2026). Neoadjuvant Lazertinib With or Without Chemotherapy in Patients With Resectable EGFR -Mutant Non–Small Cell Lung Cancer (NeoLazer): A Randomized, Multicenter, Phase II Trial. JCO Oncology Advances, 3(4). https://doi.org/10.1200/oa-26-00082

Vancouver

Lee DK, Lee S, Kim SH, Hong MH, Kim CG, Yeo JH, et al. Neoadjuvant Lazertinib With or Without Chemotherapy in Patients With Resectable EGFR -Mutant Non–Small Cell Lung Cancer (NeoLazer): A Randomized, Multicenter, Phase II Trial. JCO Oncology Advances. 2026;3(4). doi:10.1200/oa-26-00082

BibTeX
@article{Lee2026,
  author = {Lee, Dong Ki and Lee, Se-Hoon and Kim, Se Hyun and Hong, Min Hee and Kim, Chang Gon and Yeo, Ja Hyun and Park, Byung Jo and Kim, Ha Eun and Yang, Young Ho and Hong, Tae Hee and Jung, Inkyung and Ahn, Myung-Ju and Ahn, Jin Seok and Park, Sehhoon and Park, Seong Yong and Cho, Jong Ho and Lee, Junghee and Jeon, Yeong Jeong and Kim, Yu Jung and Cho, Sukki and Kim, Hong Kwan and Lee, Chang Young and Kim, Hye Ryun},
  title = {Neoadjuvant Lazertinib With or Without Chemotherapy in Patients With Resectable EGFR -Mutant Non–Small Cell Lung Cancer (NeoLazer): A Randomized, Multicenter, Phase II Trial},
  journal = {JCO Oncology Advances},
  year = {2026},
  volume = {3},
  number = {4},
  doi = {10.1200/oa-26-00082}
}
Kostenlos starten →